Previous 10 | Next 10 |
home / stock / tbgnf / tbgnf news
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 12 convertible bonds in Oxurion resulting in a EUR 300 ,000 capital increase. This is part of Atlas Special Opportunities, LLC ’s EUR 20 million Capital Comm...
Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200 ,000 capital increase. This is part of Atlas Special Opportunities, LLC ’s EUR 20 million Capital Commi...
Leuven, BELGIUM, Boston, MA, US – March 2 0 , 2023 – 11:30 pm CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular reti...
Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema and Announces Board Changes Trial has now enrolled more than two-thirds of total subj...
Oxurion Announces Subscription Agreement with Atlas Providing the Company with Up To € 20 Million in Funding Amendment of Kreos/Pontifax Agreement to reduce total debt Leuven, BELGIUM, Boston, MA, US – ...
Funding Program between Oxurion and Negma E nd s Leuven, BELGIUM, Boston, MA, US – March 2 , 2023 8:00 am CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic thera...
Information on the Total Number of Voting Rights (Denominator) following C onversion N otice from NEGMA Negma Group Investment Ltd. has converted 200 convertible bonds in Oxurion resulting in a EUR 500 ,000 capital increase...
Oxurion Provides Further Details Concerning the Second Amendment to Negma Funding Program Leuven, BELGIUM, Boston, MA, US – January 2 6 , 2023 8: 0 0 am CET – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next g...
Oxurion Announces Second Amendment to Negma Funding Program Leuven, BELGIUM, Boston, MA, US – January 25 , 202 3 8 :30 am – Oxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generati...
Oxurion NV press release ( OTC:TBGNF ): 1H GAAP EPS of -€0.32. Income of €0.26M (-21.2% Y/Y). For further details see: Oxurion NV GAAP EPS of -€0.32, revenue of €0.26M
News, Short Squeeze, Breakout and More Instantly...
Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024 Leuven, BELGIUM – 23 May, 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, held its annual shareholders’ ...
` Important Advances in Oxurion's R&D Program on Geographic Atrophy secondary to AMD Leuven, BELGIUM – May 6, 2024 – 6:00 PM CET , Oxurion NV (Euronext Brussels: OXUR), an innovative biopharmaceutical company based in Leuven, today announces important progress ...
Publication Annual Report – Annual Shareholders' Meeting Leuven, BELGIUM – April 15, 2024 – 05:00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, has today published its annual report for the financial year 2023. The...